COBRA PzF stenting to reduce duration of triple therapy

to demonstrate that the COBRA PzF stent with 14 days of DAPT post-stenting was superior in terms of bleeding and noninferior in terms of thromboembolic events when compared to new-generation DES and 3 to 6 months of DAPT post-stenting

prospective, multicentre, open-label, parallel group-randomised trial(noninferiority margin 5%)

patients with stable or unstable angina or acute coronary syndrome and oral anticoagulation

bleeding: BARC Class 2 (occurring beyond 14 days and 6 months), thromboembolic within 14 days